1. Home
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Oncology Precision Medicine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027

Oncology Precision Medicine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027

  • November 2022
  • 111 pages
  • ID: 6362624
  • Format: PDF
  • TechSci Research

Summary

Table of Contents

Oncology Precision Medicine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027
By Ecosystem (Precision Diagnostics, Precision Therapeutics, Applied Sciences, Digital Health, and Information Technology), Precision Diagnostics (Molecular Diagnostics v/s Medical Imaging), Precision Therapeutics (Clinical Trials, Cell Therapy, Drug Discovery & Research, Gene Therapy), Applied Sciences (Genomics, Pharmacogenomics, Others), Digital Health, and Information Technology (Clinical Decision Support Systems (CDSS), Big Data Analytics, Genomics Informatics, In-Silico Informatics, Others), By Application (Solid Tumor v/s Hematological Malignancies), Solid Tumor (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Others), Hematological Malignancies (Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Leukemia, Others), and By Region


The global oncology precision medicine market is expected to grow at an impressive CAGR in the forecast period, 2023-2027.Precision medicine represent the medical approach for the prevention of disease and diagnosis which is based on genetic, environmental, and behavioural variability.

It helps in illnesses susceptibility prediction, diseases diagnosis, and progression, as well as medicine prescription.It assists in taking healthcare related decisions, improving quality care, and declining inefficiencies due to the trial-and-error is also augmenting the market growth.

Precision medicine is widely utilized to diagnose the chromosomal abnormalities in the foetus and cancer and works for therapy for chronic diseases. The escalating demand of oncology precision medicine methods owing to the growing prevalence of cancer and the expanding number of treatment candidates in clinical trials are fueling the growth of the market.
Increasing Risk of Chronic Diseases in Geriatric Population Drives the Market Growth
Most cancer diagnoses occur in adults over the age of 65 years which demands the accurate treatment plan for this age group.Several oncologists use recommended and available geriatric assessments to help in evaluating older patients and guide their cancer treatment planning.

The concept of precision medicine extends beyond tumour-specific markers to incorporate host factors that are assessed as part of a routine geriatric assessment.Oncologists are always careful to stage the cancer in creating cancer treatment plans by giving the importance of staging the aging to ensure that cancer treatments are personalized to as per the patient condition.

Assessing the health status of older adults is as important and essential to optimizing treatment as assessing tumour biology and should be included alongside other precision medicine initiatives. I applaud the authors on a well-written and insightful article on implementing geriatric assessment and encourage oncology providers to use geriatric assessments in the routine care of their older patients and to apply this knowledge to individualize their care of this growing and vulnerable population.
Rise in Use of Targeted Gene Therapy is Expected to Propel the Market Growth
Gene therapy considered as one of the most lucrative markets for precision medicine organizations.Genome sequencing is an unavoidable stage of gene therapy, the extensive investments that are being made in this field drives the growth of the precision medicine market.

The increase in number of cancers is escalating the demand for gene therapy as an effective personalized treatment choice across the globe.The significant growth in the number of patients necessitates gene therapy as a potential treatment approach addressing the increasing global burden of the disease.

With this, the expanding adoption of emerging genomic technologies, including NGS and high-density microarray, along with the several government initiatives is propelling the market growth.
Market Segmentation
The global oncology precision medicine market is segmented into ecosystem, application, and regional distribution.Based on the ecosystem, the market is divided into precision diagnostics, precision therapeutics, applied sciences, digital health, and information technology.

Based on the precision diagnostics, the market is bifurcated into molecular diagnostics and medical imaging.Based on the precision therapeutics, the market is divided into clinical trials, cell therapy, drug discovery & research, gene therapy.

Based on the applied sciences, the market is divided into genomics, pharmacogenomics, others.Based on the digital health, and information technology, the market is divided into clinical decision support systems (CDSS), big data analytics, genomics informatics, in-silico informatics, others.

Based on application, the market is segmented into insect scouting, crop disease scouting, weed scouting, others. Based on application, the market is bifurcated into solid tumor and hematological malignancies. Based on solid tumor, the market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, others. Based on hematological malignancies, the market is divided into hodgkin lymphoma, non-hodgkin lymphoma, leukemia, others. The market analysis also studies the regional segmentation, divided among North American region, Asia-Pacific region, European region, South American region, and Middle East & African region.
Market Players
Novartis AG, F. Hoffmann-La Roche AG, Merck & Co., Inc., Danaher Corporation, Abbott Laboratories, Inc., Quest Diagnostics Inc, Eurofins Genomics LLC, Laboratory Corporation of America Holdings, Thermos Fischer Scientific, Inc., bioMérieux SA are the leading market players contributing the growth of the global oncology precision medicine market.

Report Scope:

In this report, global oncology precision medicine market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
• Oncology Precision Medicine Market, By Ecosystem:
o Precision Diagnostics
o Precision Therapeutics
o Applied Sciences
o Digital Health
o Information Technology
• Oncology Precision Medicine Market, By Precision Diagnostics:
o Molecular Diagnostics
o Medical Imaging
• Oncology Precision Medicine Market, By Precision Therapeutics:
o Clinical Trials
o Cell Therapy
o Drug Discovery & Research
o Gene Therapy
• Oncology Precision Medicine Market, By Applied Sciences:
o Genomics
o Pharmacogenomics
o Others
• Oncology Precision Medicine Digital Health, and Information Technology:
o Clinical Decision Support Systems (CDSS)
o Big Data Analytics
o Genomics Informatics
o In-Silico Informatics
o Others
• Oncology Precision Medicine Market, By Application:
o Solid Tumor
o Hematological Malignancies
• Oncology Precision Medicine Market, By Solid Tumor:
o Breast Cancer
o Lung Cancer
o Colorectal Cancer
o Prostate Cancer
o Others
• Oncology Precision Medicine Market, By Hematological Malignancies:
o Hodgkin Lymphoma
o Non-Hodgkin Lymphoma
o Leukemia
o Others
• Oncology Precision Medicine Market, By Region:
o North America
United States
Canada
Mexico
o Asia-Pacific
China
India
Japan
South Korea
Australia
Singapore
Malaysia
o Europe
Germany
United Kingdom
France
Italy
Spain
Poland
Denmark
o South America
Brazil
Argentina
Colombia
Peru
Chile
o Middle East & Africa
Saudi Arabia
South Africa
UAE
Iraq
Turkey

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global oncology precision medicine market.

Available Customizations:

With the given market data, we offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • $ 3500
  • December 2022
  • 83 pages

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Sum ...

  • World
  • Cancer
  • Pharmaceutical
  • Industry analysis
  • Prescription Drug Sales

ref:plp2022

Reportlinker.com © Copyright 2023. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on